APA citiranje

Tullius, M. V., Harth, G., Masleša-Galić, S., Dillon, B. J., & Horwitz, M. A. (2008). A Replication-Limited Recombinant Mycobacterium bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious than BCG. American Society for Microbiology (ASM).

Citação norma Chicago

Tullius, Michael V., Günter Harth, Saša Masleša-Galić, Barbara J. Dillon, and Marcus A. Horwitz. A Replication-Limited Recombinant Mycobacterium Bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious Than BCG. American Society for Microbiology (ASM), 2008.

MLA citiranje

Tullius, Michael V., et al. A Replication-Limited Recombinant Mycobacterium Bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious Than BCG. American Society for Microbiology (ASM), 2008.